Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.

The post Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio appeared first on Investor’s Business Daily.